Randomized, Phase II Trial of Intravenous Ascorbic Acid (Vitamin C) as an Adjunct to Pazopanib in the First-Line Setting for Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (ccRCC)
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2019
At a glance
- Drugs Ascorbic acid (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Apr 2018 Planned End Date changed from 1 Mar 2020 to 1 Jun 2021.
- 13 Apr 2018 Planned primary completion date changed from 1 Mar 2020 to 1 Aug 2020.